Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Gross Profit (2016 - 2018)

Theravance Biopharma (TBPH) has disclosed Gross Profit for 6 consecutive years, with $7.5 million as the latest value for Q1 2018.

  • Quarterly Gross Profit rose 197.11% to $7.5 million in Q1 2018 from the year-ago period, while the trailing twelve-month figure was $14.3 million through Mar 2018, down 53.25% year-over-year, with the annual reading at $9.4 million for FY2017, 22.72% down from the prior year.
  • Gross Profit for Q1 2018 was $7.5 million at Theravance Biopharma, up from $1.4 million in the prior quarter.
  • The five-year high for Gross Profit was $20.0 million in Q1 2015, with the low at -$1.8 million in Q4 2014.
  • Average Gross Profit over 5 years is $6.3 million, with a median of $4.5 million recorded in 2016.
  • Peak annual rise in Gross Profit hit 53800.0% in 2014, while the deepest fall reached 1122.29% in 2014.
  • Over 5 years, Gross Profit stood at -$1.8 million in 2014, then soared by 138.68% to $692000.0 in 2015, then skyrocketed by 556.94% to $4.5 million in 2016, then plummeted by 69.23% to $1.4 million in 2017, then skyrocketed by 435.6% to $7.5 million in 2018.
  • According to Business Quant data, Gross Profit over the past three periods came in at $7.5 million, $1.4 million, and $3.3 million for Q1 2018, Q4 2017, and Q3 2017 respectively.